Looking at New Treatment Options for High-Risk Chronic Lymphocytic Leukemia
NCT04169737 · RecruitingThis clinical trial is looking at how well three medicines work together for patients with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if adding obinutuzumab to acalabrutinib and venetoclax can help improve patient outcomes. Acalabrutinib and venetoclax may help stop cancer cells from growing, and obinutuzumab may boost the immune system to fight the cancer better.
Locations and contact
This trial is running at 1 location in the United States. It is currently recruiting.
United States1 location · 1 recruiting
- M D Anderson Cancer CenterHouston, TexasRecruiting
Who can join
Patients aged 18 and older can join. This trial is open to men and women with a diagnosis of CLL or SLL. Participants should have either high-risk features or have had prior treatments that didn’t work. The trial team will confirm if someone is eligible to participate.
What happens during the trial
Participants will be randomly placed into one of two groups. Group one will receive acalabrutinib, venetoclax, and obinutuzumab. Group two will get acalabrutinib and venetoclax without obinutuzumab. Everyone will receive treatment for up to 26 cycles unless there are issues with disease or side effects.
The trial team
This trial is sponsored by M.D. Anderson Cancer Center, with collaboration from the National Cancer Institute, AstraZeneca, and Genentech, Inc. Dr. William G Wierda is the principal investigator leading the study.
Important dates
The trial started on July 29, 2020, and is expected to finish by July 9, 2026. It is currently recruiting new participants.
Additional information
The trial's ID number is NCT04169737. It is a Phase 2 trial, which means it is looking closely at how well the treatments work and how safe they are. The study is FDA-regulated and aims to include about 168 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →